<SEC-DOCUMENT>0001213900-19-006723-index.html : 20190418
<SEC-HEADER>0001213900-19-006723.hdr.sgml : 20190418
<ACCEPTANCE-DATETIME>20190418172439
ACCESSION NUMBER:		0001213900-19-006723
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		9
CONFORMED PERIOD OF REPORT:	20190418
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190418
DATE AS OF CHANGE:		20190418

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36374
		FILM NUMBER:		19756680

	BUSINESS ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		646-677-3875

	MAIL ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k041819_actiniumpharma.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
Document 1 - file: f8k041819_actiniumpharma.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>f8k041819ex1-1_actinium.htm
<DESCRIPTION>UNDERWRITING AGREEMENT, DATED AS OF APRIL 18, 2019, BY AND BETWEEN ACTINIUM PHARMACEUTICALS, INC. AND WILLIAM BLAIR & COMPANY, L.L.C.
<TEXT>
Document 2 - file: f8k041819ex1-1_actinium.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>f8k041819ex4-1_actinium.htm
<DESCRIPTION>FORM OF WARRANT
<TEXT>
Document 3 - file: f8k041819ex4-1_actinium.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>f8k041819ex5-1_actinium.htm
<DESCRIPTION>OPINION OF THE MATT LAW FIRM, PLLC.
<TEXT>
Document 4 - file: f8k041819ex5-1_actinium.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>f8k041819ex99-1_actinium.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY ACTINIUM PHARMACEUTICALS, INC. DATED APRIL 17, 2019
<TEXT>
Document 5 - file: f8k041819ex99-1_actinium.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>6
<FILENAME>f8k041819ex99-2_actinium.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY ACTINIUM PHARMACEUTICALS, INC. DATED APRIL 18, 2019
<TEXT>
Document 6 - file: f8k041819ex99-2_actinium.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 7 - file: ex5-1_001.jpg

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 8 - file: ex99-1_001.jpg

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex99-2_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 9 - file: ex99-2_001.jpg

</DOCUMENT>
</SEC-DOCUMENT>